Juvenile Immunotoxicology

Toxicologic Pathology

Volumn 40, Issue 2, 2012, Pages 248-254

  Holsapple, Michael P ^a   O’lone, Raegan ^a  

^a ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

Author keywords

developmental and reproductive toxicity (DART); developmental immunotoxicity (DIT); immune system; juvenile toxicity; pharmaceuticals

Indexed keywords

ADOLESCENT; ADOLESCENT DISEASE; ALLERGIC ASTHMA; ASSAY; AUTOIMMUNITY; CLINICAL TRIAL (TOPIC); EMBRYO DEVELOPMENT; FETUS DEVELOPMENT; HISTOPATHOLOGY; HUMAN; IMMUNE SYSTEM; IMMUNOTOXICITY; IN VITRO STUDY; JUVENILE; NEUROTOXICITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING;

CHILD; CHILD, PRESCHOOL; DEVELOPMENTAL DISABILITIES; HUMANS; IMMUNE SYSTEM; IMMUNOTOXINS;

EID: 84858789421     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623311427708     Document Type: Article

References (28)

1. Burns-Naas L. A. Hastings K. L. Ladics G. S. Makris S. L. Parker G. A. Holsapple M. P. (2008). Invited review: What’s so special about the developing immune system? Int J Toxicol 27, 223–54.
2. Cappon G. D. Bailey G. P. Buschmann J. Feuston M. Fisher J. E. Hew K. W. Hoberman A. M. Ooshima Y. Stump D. G. Hurtt M. E. (2009). Juvenile animal toxicity study designs to support pediatric drug development. Birth Defects Res B Dev Reprod Toxicol 86, 463–69.
3. Carleer J. Karres J. (2011). Juvenile animal studies and pediatric drug development: a European regulatory perspective. Birth Defects Res B Dev Reprod Toxicol [Epub ahead of print].
4. Cooper R. L. Lamb J. C. Barlow S. M. Bentley K. Brady A. M. Doerrer N. G. Eisenbrandt D. L. Fenner-Crisp P. A. Hines R. N. Irvine L. F. Kimmel C. A. Koeter H. Li A. A. Makris S. L. Sheets L. P. Speijers G. Whitby K. E. (2006). A tiered approach to life stages testing for agricultural chemical safety assessment. Crit Rev Toxicol 36, 69–98.
5. Dietert R. R. Burns-Naas L. A. (2008). Developmental immunotoxicity in rodents. In Immunotoxicology Strategies for Pharmaceutical Safety Assessment (Herzyk D. J. Bussiere J. L., eds.), pp. 273–97. John Wiley & Sons, Inc., Hoboken, NJ.
6. Dietert R. R. Holsapple M. P. (2007). Methodologies for developmental immunotoxocity (DIT) testing. Methods 41, 123–31.
7. Dietert R. R. Piepenbrink M. S.(2006). Perinatal immunotoxicity: why adult exposure assessment fails to predict risk. Environ Health Perspect 114, 477–83.
8. Dietert R. R. Etzel R. A. Chen D. Halonen M. Holladay S. D. Jarabek A. M. Landreth K. Peden D. B. Pinkerton K. Smialowicz R. J. Zoetis T. (2000). Workshop to identify critical windows of exposure for children’s health: immune and respiratory systems work group summary. Environ Health Perspect 108(Suppl 3), 483–90.
9. European Medicines Agency, Committee for Human Medicinal Products (EMA) (2008). Guideline on the need for non-clinical testing in juvenile animals of pharmaceuticals for paediatric indications. 2008.
10. Holsapple M. P. (2002). Developmental immunotoxicology and risk assessment: a workshop summary. Human Exp Toxicol 21, 473–78.
11. Holsapple M. P. (2003). Developmental immunotoxicity testing: a review. Toxicology 185, 193–203.
12. Holsapple M. P. West L. J. Landreth K. S. (2003). Species comparison of anatomical and functional immune system developmnt. Birth Defects Res 68, 321–34.
13. Holsapple M. P. Paustenbach D. J. Charnley G. West L. J. Luster M. I. Dietert R. R. Burns-Naas L. (2004). Symposium summary: children’s health risk – what’s so special about the developing immune system? Toxicol Appl Pharmacol 199, 61–70.
14. Holsapple M. P. Burns-Naas L. A. Hastings K. Ladics G. S. Lavin A. L. Makris S. Yang Y. Luster M. I. (2005). A proposed testing framework for developmental immunotoxicology (DIT). Toxicol Sci 83, 18–24.
15. Holsapple M. P. van der Laan J. W. van Loveren H. (2007). Development of a framework for developmental immunotoxicity testing. In Immunotoxicology and Immunopharmacology, 3rd ed. (Kimber I. House R. Luebke R., eds.), pp. 347–61. CRC Press, Baco Raton, FL.
16. Kimura S. Eldridge J. H. Michalek S. M. Morisaki I. Hamada S. McGhee J. R. (1985). Immunoregulation in the rat: ontogeny of B cell responses to types 1, 2, and T-dependent antigens. J Immunol 134, 2839–46.
17. Ladics G. S. Smith C. Bunn T. L. Dietert R. R. Anderson P. K. Wiescinski C. M. Holsapple M. P. (2000). Characterization of an approach to developmental immunotoxicology assessment in the rat using SRBC as the antigen. Toxicol Methods 10, 283–311.
18. Ladics G. S. Chapin R. E. Hastings K. L. Holsapple M. P. Makris S. L. Sheets L. P. Woolhiser M. R. Burns-Naas L. A. (2005). Developmental toxicology evaluations: issues with including neurotoxicology and immunotoxicology assessments in reproductive toxicology studies. Toxicol Sci 88, 24–29.
19. Leconte I. Bailey G. Davis-Bruno K. Hew K. W. Kim J. H. Silva Lima B. Liminga U. W. Moffit J. De Schaepdrijver L. Schmitt G. Tassinari M. S. Thompson K. Hurtt M. E. Workshop summary: value of juvenile animal studies. Birth Defects Res B Dev Reprod Toxicol. In press.
20. Luebke R. W. Chen D. H. Dietert R. Yang Y. King M. Luster M. I. (2006). The comparative immunotoxicity of five selected compounds following developmental or adult exposure. Immunotoxicology Workgroup. J Toxicol Environ Health B Crit Rev 9, 1–26.
21. Luster M. I. Dean J. H. Germolec D. R. (2003). Consensus workshop on methods to evaluate developmental immunotoxicity. Environ Health Perspect 111, 579–83.
22. Martin P. L. Breslin W. Rocca M. Wright D. Cavagnaro J. (2009). Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals. Birth Defects Res B Dev Reprod Toxicol 86, 176–203.
23. Shimomura K. (2011). The value of juvenile animal studies: a Japanese industry perspective. Birth Defects Res B Dev Reprod Toxicol. doi: 10.1002/bdrb.20300. [Epub ahead of print]
24. Stewart J. (2009). Developmental toxicity testing of monoclonal antibodies: an enhanced pre- and postnatal study design option. Reprod Toxicol 28, 220–25.
25. Tassinari M. S. Benson K. Elayan I. Espandiari P. Davis-Bruno K. (2011). Juvenile animal studies and pediatric drug development retrospective review: use in regulatory decisions and labeling. Birth Defects Res B Dev Reprod Toxicol. doi: 10.1002/bdrb.20304. [Epub ahead of print]
26. United States Food and Drug Administration (FDA) (2006). Guidance for Industry-Nonclinical Safety Evaluation of Pediatric Drug Products. Office of Training and Communication. Division of Drug Information, Center for Drug Evaluation and Research, U.S. Department of Health and Human Services. 2006.
27. Vogel R. Seidle T. Spielmann H. (2010) A modular one-generation reproduction study as a flexible testing system for regulatory safety assessment. Reprod Toxicol 29, 242–45.
28. Weinstock D. Lewis D. B. Parker G. A. Beyer J. Collinge M. Brown T. P. Dybal N. (2010). Toxicopathology of the developing immune system: investigative and development strategies. Toxicol Pathol 38, 1111–17.